Validating genomic tools for precision medicine in chronic lymphocytic leukemia: ERIC leads the way

Haematologica. 2021 Mar 1;106(3):656-658. doi: 10.3324/haematol.2020.270652.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Intramural
  • Comment

MeSH terms

  • Genomics
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell* / diagnosis
  • Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
  • Leukemia, Lymphocytic, Chronic, B-Cell* / therapy
  • Mutation
  • Precision Medicine

Grants and funding

Funding: Support received for work outside the submitted work: Adrian Wiestner received research support from Pharmacyclics LLC, an AbbVie company; Acerta Pharma, a member of the Astra-Zeneca group; Merck; Nurix; and Genmab. The author is supported by the intramural research program of NHLBI, NIH.